O. Abdel-wahab, T. Manshouri, J. Patel, K. Harris, J. Yao et al., Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias, Cancer Research, vol.70, issue.2, pp.447-452
DOI : 10.1158/0008-5472.CAN-09-3783

O. Abdel-wahab, O. Kilpivaara, J. Patel, L. Busque, and R. Levine, The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration, Leukemia, vol.70, issue.9, pp.1656-1657, 2010.
DOI : 10.1038/leu.2010.144

A. Alvarez-larr-an, B. Bellosillo, A. Pereira, A. Kerguelen, C. Hern-andez-boluda et al., V617F monitoring in polycythemia vera and essential thrombocythemia: Clinical usefulness for predicting myelofibrotic transformation and thrombotic events, American Journal of Hematology, vol.120, issue.5, pp.517-523, 2014.
DOI : 10.1002/ajh.23676

M. Gcc, W. Erber, and A. Green, Chromosomes & Cancer DOI 10 Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders, Genes Cancer Genome Project Lancet, vol.365, pp.1054-1061, 1002.

P. Beer, F. Delhommeau, J. Lecouedic, M. Dawson, E. Chen et al., Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm, Blood, vol.115, issue.14, pp.2891-2900, 2010.
DOI : 10.1182/blood-2009-08-236596

M. Brecqueville, J. Rey, F. Bertucci, E. Coppin, P. Finetti et al., in myeloproliferative neoplasms, Genes, Chromosomes and Cancer, vol.478, issue.8, pp.743-755, 2012.
DOI : 10.1002/gcc.21960

M. Brecqueville, J. Rey, R. Devillier, A. Guille, R. Gillet et al., Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase, Haematologica, vol.99, issue.1, pp.37-45, 2014.
DOI : 10.3324/haematol.2013.091454

F. Delhommeau, S. Dupont, V. Valle, C. James, S. Trannoy et al., in Myeloid Cancers, New England Journal of Medicine, vol.360, issue.22, pp.2289-2301, 2009.
DOI : 10.1056/NEJMoa0810069

V. Gelsi-boyer, V. Trouplin, J. Ad-ela?-ide, J. Bonansea, N. Cervera et al., in myelodysplastic syndromes and chronic myelomonocytic leukaemia, British Journal of Haematology, vol.279, issue.Suppl, pp.788-800, 2009.
DOI : 10.1111/j.1365-2141.2009.07697.x

A. Green and P. Beer, Somatic mutations of IDH1 IDH2 in the leukemic transformation of myeloproliferative neoplasms, N Engl J Med, vol.362, p.368, 2010.

P. Guglielmelli, T. Lasho, G. Rotunno, J. Score, C. Mannarelli et al., The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients, Leukemia, vol.122, issue.9, pp.1804-1810, 2014.
DOI : 10.1038/leu.2014.76

A. Harutyunyan, T. Klampfl, M. Cazzola, and R. Kralovics, p53 Lesions in Leukemic Transformation, New England Journal of Medicine, vol.364, issue.5, pp.488-490, 2011.
DOI : 10.1056/NEJMc1012718

R. Itzykson, O. Kosmider, A. Renneville, M. Morabito, C. Preudhomme et al., Clonal architecture of chronic myelomonocytic leukemias, Blood, vol.121, issue.12, pp.2186-2198, 2013.
DOI : 10.1182/blood-2012-06-440347
URL : https://hal.archives-ouvertes.fr/hal-00923316

C. James, V. Ugo, L. Cou-edic, J. Staerk, J. Delhommeau et al., A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera, Nature, vol.100, issue.7037, pp.1144-1148, 2005.
DOI : 10.1182/blood-2002-09-2839

T. Klampfl, H. Gisslinger, A. Harutyunyan, H. Nivarthi, E. Rumi et al., Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms, New England Journal of Medicine, vol.369, issue.25, pp.2379-2390, 2013.
DOI : 10.1056/NEJMoa1311347

R. Kralovics, F. Passamonti, A. Buser, S. Teo, R. Tiedt et al., in Myeloproliferative Disorders, New England Journal of Medicine, vol.352, issue.17, pp.1779-1790, 2005.
DOI : 10.1056/NEJMoa051113

T. Larsen, N. Pallisgaard, M. Møller, and H. Hasselbalch, The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis ??? impact on disease phenotype, European Journal of Haematology, vol.365, issue.6, pp.508-515, 2007.
DOI : 10.1038/sj.leu.2404209

T. Larsen, J. Christensen, H. Hasselbalch, and N. Pallisgaard, The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders, British Journal of Haematology, vol.86, issue.5, pp.745-751, 2007.
DOI : 10.1111/j.1365-2141.2005.05764.x

R. Levine, M. Wadleigh, J. Cools, B. Ebert, G. Wernig et al., Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis, Cancer Cell, vol.7, issue.4, pp.387-397, 2005.
DOI : 10.1016/j.ccr.2005.03.023

P. Lundberg, A. Karow, R. Nienhold, R. Looser, H. Hao-shen et al., Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms, Blood, vol.123, issue.14, pp.2220-2228, 2014.
DOI : 10.1182/blood-2013-11-537167

C. Ortmann, D. Kent, J. Nangalia, Y. Silber, D. Wedge et al., Effect of Mutation Order on Myeloproliferative Neoplasms, New England Journal of Medicine, vol.372, issue.7, pp.601-612, 2015.
DOI : 10.1056/NEJMoa1412098

A. Pardanani, T. Lasho, C. Finke, S. Oh, J. Gotlib et al., LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations, Leukemia, vol.118, issue.10, pp.1713-1718, 2010.
DOI : 10.1158/0008-5472.CAN-09-3783

A. Pardanani, T. Lasho, C. Finke, M. Mai, R. Mcclure et al., IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms, Leukemia, vol.28, issue.6, pp.1146-1151, 2010.
DOI : 10.1084/jem.20092506

F. Passamonti, L. Malabarba, E. Orlandi, C. Baratè, A. Canevari et al., Polycythemia vera in young patients: A study on the long-term risk of thrombosis myelofibrosis leukemia, Haematologica, vol.88, pp.13-18, 2003.

F. Passamonti, E. Rumi, L. Arcaini, E. Boveri, C. Elena et al., Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients, Haematologica, vol.93, issue.11, pp.1645-1651, 2008.
DOI : 10.3324/haematol.13346

F. Passamonti, E. Rumi, D. Pietra, C. Elena, E. Boveri et al., A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications, Leukemia, vol.22, issue.9, pp.1574-1579, 2010.
DOI : 10.1038/leu.2010.148

Y. Pikman, B. Lee, T. Mercher, E. Mcdowell, B. Ebert et al., MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia, PLoS Medicine, vol.102, issue.7, pp.1140-1151, 2006.
DOI : 10.1371/journal.pmed.0030270.st001

R. Rampal, J. Ahn, O. Abdel-wahab, M. Nahas, K. Wang et al., Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms, Proceedings of the National Academy of Sciences, vol.111, issue.50, pp.5401-5410, 2014.
DOI : 10.1182/blood-2009-04-218842

J. Robinson, H. Thorvaldsd-ottir, W. Winckler, M. Guttman, E. Lander et al., Integrative genomics viewer, Nature Biotechnology, vol.306, issue.1, pp.24-26, 2011.
DOI : 10.1093/bioinformatics/btp472
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346182

F. Schaub, R. Looser, S. Li, H. Hao-shen, T. Lehmann et al., Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms, Blood, vol.115, issue.10, pp.2003-2007, 2010.
DOI : 10.1182/blood-2009-09-245381

S. Schnittger, C. Eder, S. Jeromin, T. Alpermann, A. Fasan et al., ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome, Leukemia, vol.27, issue.1, pp.82-91, 2013.
DOI : 10.1056/NEJMoa1005143

L. Shlush, S. Zandi, A. Mitchell, W. Chen, J. Brandwein et al., Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia, Nature, vol.77, issue.7488, pp.328-333, 2014.
DOI : 10.1093/nar/gkr1073

A. Tefferi, A. Pardanani, K. Lim, O. Abdel-wahab, T. Lasho et al., TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis, TET2 mutations their clinical correlates in polycythemia vera essential thrombocythemia myelofibrosis, pp.905-911, 2009.
DOI : 10.1038/leu.2009.47
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654629

A. Tefferi, T. Lasho, O. Abdel-wahab, P. Guglielmelli, J. Patel et al., IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis, Leukemia, vol.114, issue.7, pp.1302-1309, 2010.
DOI : 10.1182/blood-2008-12-194548

A. Tefferi, E. Rumi, G. Finazzi, H. Gisslinger, A. Vannucchi et al., Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study, Leukemia, vol.12, issue.9, pp.1874-1881, 2013.
DOI : 10.1056/NEJMoa1013343
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3768558

E. Tenedini, I. Bernardis, V. Artusi, L. Artuso, E. Roncaglia et al., Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms, Leukemia, vol.28, issue.5, pp.1052-1059, 2014.
DOI : 10.1002/gcc.20502
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017260

A. Theocharides, M. Boissinot, F. Girodon, R. Garand, S. Teo et al., Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation., Blood, vol.110, issue.1, pp.375-379, 2007.
DOI : 10.1182/blood-2006-12-062125

R. Tiedt, H. Hao-shen, M. Sobas, R. Looser, S. Dirnhofer et al., Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice, Blood, vol.111, issue.8, pp.3931-3940, 2008.
DOI : 10.1182/blood-2007-08-107748

A. Vannucchi, T. Lasho, P. Guglielmelli, F. Biamonte, A. Pardanani et al., Mutations and prognosis in primary myelofibrosis, Leukemia, vol.27, issue.9, pp.1861-1869, 2013.
DOI : 10.1200/JCO.2010.32.9490

K. Yoshida, M. Sanada, Y. Shiraishi, D. Nowak, Y. Nagata et al., Frequent pathway mutations of splicing machinery in myelodysplasia, Nature, vol.451, issue.7367, pp.64-69, 2011.
DOI : 10.1038/nature10496

S. Zhang, R. Rampal, T. Manshouri, J. Patel, N. Mensah et al., Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome, Blood, vol.119, issue.19, pp.4480-4485, 2012.
DOI : 10.1182/blood-2011-11-390252